Ty-jour a2 - Moriwaki，Yoshihiro Au - Roselli，Jenny Au - Innocenti，Tommaso Au - Lynch，Erica Nicola Au - Parisio，Laura Au - Macrì，Giuseppe Au - Milla，Monica Au - Mello，Tommaso Au - Galli，Andrea Au- Milani, Stefano AU - Tarocchi, Mirko PY - 2020 DA - 2020/01/29 TI - Increased Risk of Liver Cirrhosis during Azathioprine Therapy for Crohn’s Disease SP - 6726384 VL - 2020 AB - Azathioprine is a cornerstone of the therapy of Crohn’s disease. Unfortunately, infections and malignancies are relatively common adverse effects related to this drug; however, cirrhosis is exceptionally reported as a side effect. We report the case of a 49-year-old male patient with ileocolonic steno-penetrating Crohn’s disease who developed hepatic cirrhosis while treated with azathioprine. After taking azathioprine for 3 years with regular follow-up, he developed pancytopenia, and liver cirrhosis was diagnosed with ultrasound, abdomen computed tomography scan, transient elastography, and liver biopsy. As all other causes of liver damage were excluded, azathioprine was believed to be the cause of liver injury and therefore was interrupted. SN - 2090-6528 UR - https://doi.org/10.1155/2020/6726384 DO - 10.1155/2020/6726384 JF - Case Reports in Gastrointestinal Medicine PB - Hindawi KW - ER -